Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069937 | 0.83 | MEN1 (0.50) | KMT2AMEN1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL11172692 | 0.83 | TSHR (0.54) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL17667166 | 0.79 | ALDH1A1 (0.55) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL17667165 | 0.79 | ALDH1A1 (0.55) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5790489 | 0.75 | POLB (0.69) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL180384 | 0.74 | NPC1 (0.73) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL6070102 | 0.73 | ALOX5 (0.50) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6070017 | 0.73 | ALOX5 (0.50) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3095761 | 0.73 | NPC1 (0.70) | NPC1RAB9ACA12CA9KMT2A | |
| Hydrochloric Acid SCHEMBL11786759 | 0.73 | NPC1 (0.70) | NPC1RAB9ACA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056947-B2 | For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases | GEORGIA TECH RESEARCH CORP. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040048327-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-11 | — | — | US | disclosed |
| WO-2004005270-A1 | AZA-PEPTIDE EPOXIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048327-A1 | Aza-peptide epoxides | ANPEP, ENPEP, TMPRSS15 | NPC1 722/4885RAB9A 1416/4885CA12 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.